Branded Legacy Subsidiary Partners with McMaster University to Evaluate Addiction Treatment Solutions
Branded Legacy's subsidiary Bio-Legacy Evaluative Group has formed a strategic partnership with McMaster University to advance rigorous evaluations and clinical trials for addiction interventions, aiming to reduce overdose deaths and promote recovery.
Branded Legacy, Inc. (OTC: BLEG) announced that its wholly owned subsidiary, Bio-Legacy Evaluative Group, has partnered with McMaster University to evaluate innovative products for populations affected by addictions. The collaboration combines McMaster's expertise in addiction medicine, clinical trials, and guideline development with Bio-Legacy's real-world scientific experience to advance rigorous evaluations, clinical trials, and regulatory submissions.
This partnership supports the development of accessible, cost-effective interventions aimed at reducing overdose deaths, minimizing drug-related harms, and promoting long-term recovery. Branded Legacy is a holdings company focused on health and wellness, developing innovative solutions to combat addiction by preventing overdoses and supporting recovery. Its patented intranasal naloxone delivery device enhances accessibility and dosing precision for opioid overdose treatment.
The platform also enables nasal delivery of vaccines and other medications, opening opportunities in global markets for rapid pandemic response and improved access in underserved regions. For more information about the company, visit https://BrandedLegacy.com. The full press release can be viewed at https://ibn.fm/8ojxr.